On May 22, Abivax S.A. rose 5.09% in regular trading, trading at $125.505/share, with trading volume of $97.48 million.

On the news front, Abivax S.A. is scheduled to release its earnings report on May 25 before market open. Although quarterly revenue is expected to decline 88.78% year-over-year, institutional bullish sentiment is dominant. Most sell-side analysts maintain a buy rating on the company with target prices above the current trading range. Market attention is focused on the impact of financing and royalty arrangements on expenses and cash flow trajectory.

Last quarter, Abivax S.A. reported revenue of EUR 440,000, gross margin of 100%, net loss attributable to shareholders of EUR 81.96 million, and adjusted EPS of -EUR 1.14. The stock has gained momentum over recent sessions, rising 5.18% on May 20, reflecting growing pre-earnings optimism.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases, with its lead candidate obefazimod in Phase 3 trials for ulcerative colitis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)